Gareth Owain Richards

Dr. Gareth Owain Richards

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
YZYuhan Zhou
Yuhan Zhou
FZFeier Zeng
Feier Zeng
GRGareth Owain Richards
Gareth Owain Richards
NWNing Wang
Ning Wang
Prostate cancer (PCa) is the second leading cause of male cancer deaths in the UK and the fifth worldwide. The presence of distant PCa metastasis can reduce the 5-year survival rate from 100% to approximately 30%. Enolase 2 (ENO2), a crucial glycolytic enzyme in cancer metabolism, is associated with the metastasis of multiple cancers and is also used as a marker for neuroendocrine tumours. However, its role in PCa metastasis remains unclear. In this study, we systematically reviewed the current literature to determine the association between ENO2 and metastatic PCa. Medline, Web of Science, and PubMed were searched for eligible studies. The search yielded five studies assessing ENO2 expression in PCa patients or cell lines. The three human studies suggested that ENO2 expression is correlated with late-stage, aggressive PCa, including castrate-resistant PCa (CRPC), metastatic CRPC, and neuroendocrine PCa (NEPC). This was further supported by two in vitro studies indicating that ENO2 expression can be regulated by the tumour microenvironment, such as androgen deprived conditions and the presence of bone-forming osteoblasts. Therefore, ENO2 may functionally contribute to PCa metastasis, possibly due to the unique metabolic features of PCa, which are glycolysis dependent only at the advanced metastatic stage.

25 June 2020 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
PAParis Avgoustou
Paris Avgoustou
Ameera JailaniAmeera Jailani
Ameera Jailani
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
GRGareth Owain Richards
Gareth Owain Richards

2 August 2017 in Current Molecular Biology Reports
Verified
Journal Article
Open access
PDF file
JWJessica Isabel Warrington
Jessica Isabel Warrington
GRGareth Owain Richards
Gareth Owain Richards
NWNing Wang
Ning Wang
Purpose of Review This study is to highlight recent discoveries associated with the role of calcitonin peptide family and their receptors in prostate cancer progression and bone metastasis. Recent Findings Studies have linked adrenomedullin (AM), calcitonin (CT) and calcitonin gene-related peptide (CGRP) to the spread of prostate tumours to the bone. AM can induce a metastatic phenotype in prostate cancer cells through its action on TRPV2 calcium channels and is also capable of influencing localised levels of RANKL in the bone to favour tumourigenesis. CT utilises A-kinase anchoring proteins to indirectly act on PKA and promote metastasis in prostate cancer. The receptor for CT contains a PDZ-binding domain, the deletion of which stops metastasis to the bone in orthotopic prostate models. Summary Recent findings show strong evidence for the role of calcitonin peptides and receptors in prostate cancer and bone metastasis. Further research could provide potential prognostic markers and therapeutic targets for prostate cancer patients.

22 June 2022 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
Ameera JailaniAmeera Jailani
Ameera Jailani
KBKamilla J. A. Bigos
Kamilla J. A. Bigos
PAParis Avgoustou
Paris Avgoustou
JEJoseph L. Egan
Joseph L. Egan
RHRobert A. Hathway
Robert A. Hathway
GRGareth Owain Richards
Gareth Owain Richards
Adrenomedullin (AM) is a peptide responsible for many physiological processes including vascular health and hormone regulation. Dysregulation of AM signaling can stimulate cancers by promoting prol...

5 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
Ameera JailaniAmeera Jailani
Ameera Jailani
PAParis Avgoustou
Paris Avgoustou
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
JHJoe Harrity
Joe Harrity
Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists.

23 September 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PAParis Avgoustou
Paris Avgoustou
AJAmeera B. A. Jailani
Ameera B. A. Jailani
ADAditya J. Desai
Aditya J. Desai
DRDavid J. Roberts
David J. Roberts
ELEwan R. Lilley
Ewan R. Lilley
GRGareth Owain Richards
Gareth Owain Richards
Introduction: Receptor activity-modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G-protein-coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. This study investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTH and PTH-related protein (PTHrP)-derived ligands.Methods: We employed FRET imaging to assess PTH1R interactions with RAMPs. Cell surface expression of PTH1R was evaluated in the presence of RAMPs. PTH1R-mediated cAMP accumulation, β-arrestin recruitment, and calcium signalling were measured in response to various ligands. Antibody-capture scintillation proximity assays were used to examine G-protein activation patterns.Results: PTH1R preferentially interacted with RAMP2 and, to a lesser extent, RAMP3, but not with RAMP1. RAMP3 co-expression reduced cell surface expression of PTH1R. RAMP2 significantly enhanced PTH1R-mediated signalling responses to PTH (1-34), PTHrP (1-34), PTH (1-84), and PTH (1-17) analogue ZP2307, while RAMP3 co-expression attenuated or abolished these responses. Full-length PTHrP analogues exhibited lower potency and efficacy than PTHrP (1-34) in activating PTH1R. RAMP2 increased the potency and/or efficacy of these analogues, whereas RAMP3 reduced these responses. RAMP2 differentially modulated G-protein activation by PTH1R in a ligand-dependent manner, with PTH (1-34) and PTHrP (1-34) inducing distinct patterns of G-protein subtype activation.Discussion: These findings highlight the complex role of RAMPs in regulating PTH1R signalling and trafficking, revealing differential effects of RAMP2 and RAMP3 on receptor function. The data suggest that targeting the PTH1R/RAMP2 complex may be a promising strategy for developing novel bone anabolic therapies by leveraging biased agonism and functional selectivity. Further research using physiologically relevant models is needed to elucidate the therapeutic potential of this approach.